COMPANY:

ArteraAI

"Artera...announced today it has received its California laboratory license from the California Department of Public Health (CDPH). This licensure allows Artera to offer its innovative ArteraAI Prostate Test to one of the largest healthcare markets in the United States."

"Artera...launched the first artificial intelligence (AI) test to guide patients in making informed decisions between active surveillance and active treatment based on an analysis of digital pathology images."

"Artera...will present three abstracts at the 2024 ASCO Annual Meeting demonstrating that its multimodal artificial intelligence (MMAI) platform provides significant prognostic value across various stages of prostate cancer and for early stage breast cancer. These studies build upon the first AI-enabled test that delivers prognostic and predictive insights for localized prostate cancer patients: ArteraAI Prostate Test...The MMAI platform can provide results to support personalized therapy by combining a patient’s unique clinical data with their pathology slides. Artera is taking a unique approach to this by applying AI to images of hematoxylin and eosin (H&E)-stained pathology slides to provide prognostic and predictive results."

"ArteraAI...announced the validation of its first multimodal artificial intelligence (MMAI) digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence (BCR)."

"ArteraAI...announced its continued work with Movember...This announcement follows a recent study presented at the 2023 European Society for Medical Oncology Congress (ESMO). The study successfully validated ArteraAI's prognostic model in advanced prostate cancer, demonstrating stronger prognostic correlations than individual clinical factors."

"ArteraAI...announced today its inclusion in the newly released NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer. The ArteraAI Prostate Test is the only test included for its predictive performance. The test is also the first AI-enabled predictive and prognostic test to be recommended in the guidelines for localized prostate cancer."

"ArteraAI...announced today that it has secured an additional $20 million in capital fueled by several prominent large investment funds including Prosperity7 Ventures, Singapore-based global investor EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, and Trium Ventures, along with investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC)."

"ArteraAI...announced today that the Centers for Medicare and Medicaid Services (CMS) have decided on the payment rate for the ArteraAI Prostate Test, a Clinical Diagnostic Laboratory Test (CDLT). The rate became effective on Jan. 1, 2024."

"ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today a research agreement with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory headquartered in Carolina, Puerto Rico. The collaboration aims to further validate The ArteraAI Prostate Test in the Hispanic population."